What Is Ergothioneine?
Ergothioneine (abbreviated ERGO or ET) is a naturally occurring amino acid with a distinctive sulfur-containing imidazole ring structure. First discovered in 1909 in ergot fungi, it has since been identified in a wide range of organisms — though humans cannot synthesize it and must obtain it from dietary sources.
What makes ergothioneine unusual among antioxidants is its dedicated transporter. Humans express a specific protein called OCTN1 (organic cation transporter novel type 1), encoded by the SLC22A4 gene, whose primary function appears to be absorbing and retaining ergothioneine. The existence of a dedicated transporter strongly suggests that ergothioneine plays an important biological role — the body wouldn't maintain specialized uptake machinery for a trivial molecule.
Ergothioneine accumulates in tissues with high oxidative stress exposure: red blood cells, the liver, kidneys, bone marrow, seminal fluid, and the lens of the eye. It crosses the blood-brain barrier via OCTN1, which has fueled particular interest in its potential neuroprotective effects.
The richest dietary sources are mushrooms — particularly king oyster, maitake, shiitake, and oyster mushrooms — along with some organ meats and beans. Average dietary intake in Western populations is estimated at 1–5 mg per day, though this varies substantially with mushroom consumption.
How Ergothioneine Works
A Unique Antioxidant Profile
Ergothioneine's antioxidant chemistry is distinct from more familiar antioxidants like vitamin C, vitamin E, or glutathione. Its thione (sulfur-containing) group gives it several advantageous properties:
- Exceptional stability. Unlike glutathione, which is rapidly oxidized and consumed in reactions, ergothioneine is remarkably stable under physiological conditions. It doesn't auto-oxidize in the presence of iron or copper ions — a critical advantage because these metal-catalyzed reactions generate harmful hydroxyl radicals.
- Metal chelation. Ergothioneine can bind iron and copper ions, preventing them from catalyzing Fenton reactions that produce reactive oxygen species (ROS).
- Selective reactivity. Rather than reacting indiscriminately with all free radicals, ergothioneine preferentially scavenges the most damaging species: hydroxyl radicals, hypochlorous acid, and peroxynitrite.
This selectivity and stability mean that ergothioneine can persist in tissues for extended periods, providing sustained antioxidant protection rather than the brief burst of activity seen with many dietary antioxidants.
Mitochondrial Protection
Ergothioneine accumulates in mitochondria, the cellular organelles responsible for energy production and a major source of endogenous ROS. By scavenging mitochondrial free radicals and chelating iron within the organelle, ergothioneine may help preserve mitochondrial function during aging — a process central to many theories of biological aging.
Preclinical studies have shown that ergothioneine protects mitochondrial DNA from oxidative damage and maintains membrane potential under stress conditions. This mitochondrial-targeted activity distinguishes it from many antioxidant supplements that don't efficiently reach mitochondria.
Anti-Inflammatory Pathways
Beyond direct antioxidant activity, ergothioneine modulates inflammatory signaling. Cell-based and animal studies have demonstrated that it can:
- Inhibit NF-κB activation, a master regulator of inflammatory gene expression
- Reduce production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- Attenuate inflammatory damage in models of neuroinflammation, liver injury, and lung damage
The anti-inflammatory effects appear to be partly independent of its antioxidant activity, suggesting multiple modes of action.
Cytoprotection
Ergothioneine has demonstrated protective effects against various forms of cellular stress in laboratory models, including UV radiation damage, heavy metal toxicity, and ischemia-reperfusion injury. It also appears to inhibit certain forms of programmed cell death (ferroptosis and pyroptosis) that are driven by iron-dependent oxidative damage.
Ergothioneine Benefits: What the Research Shows
Cognitive Function — The 2025 RCT
Zajac and colleagues randomized 147 adults aged 55–79 with subjective memory complaints to 10 mg/day, 25 mg/day, or placebo for 16 weeks. The primary composite-memory outcome did not differ significantly between groups. A temporary improvement from baseline at 25 mg was not maintained. Some secondary subjective-memory and sleep-initiation findings favored supplementation, but the results were preliminary [1].
Changes within a treatment group do not by themselves show that treatment outperformed placebo. This distinction limits the clinical conclusions that can be drawn from this trial.
Longevity and Aging Biomarkers
Epidemiological research has consistently linked higher blood levels of ergothioneine with markers of healthy aging:
- A large Singaporean cohort study found that higher plasma ergothioneine levels were associated with reduced risk of cardiovascular mortality, cognitive decline, and frailty over a 10+ year follow-up period.
- Swedish population data showed that plasma ergothioneine declines with age and that lower levels correlate with increased markers of oxidative stress and inflammation.
These observational findings align with the mechanistic data but cannot prove causation. People who eat more mushrooms may differ from non-consumers in many health-relevant ways.
Neuroprotection
The brain is particularly vulnerable to oxidative stress due to its high metabolic rate, abundant polyunsaturated fatty acids, and relatively modest antioxidant defenses. Ergothioneine's ability to cross the blood-brain barrier via OCTN1 makes it a candidate for neuroprotection.
Preclinical studies have shown protective effects in models of:
- Parkinson's disease (protecting dopaminergic neurons from oxidative damage)
- Alzheimer's disease (reducing amyloid-beta-induced toxicity)
- Traumatic brain injury
- Age-related cognitive decline
The trial does not establish prevention or treatment of neurodegenerative disease. Laboratory neuroprotection should not be presented as a demonstrated patient benefit.
Cardiovascular Health
Ergothioneine's antioxidant and anti-inflammatory properties are relevant to cardiovascular health, given that oxidative stress and inflammation are central drivers of atherosclerosis. Animal studies have shown reduced arterial plaque formation and improved endothelial function with ergothioneine supplementation. Human cardiovascular data is limited to observational associations.
Eye Health
Ergothioneine concentrates in the lens and retina of the eye, suggesting a protective role against age-related eye diseases driven by oxidative damage (cataracts, macular degeneration). This is a biologically plausible but clinically unproven benefit as of 2026.
Dosage and How to Take Ergothioneine
No established daily requirement or effective dose for cognitive enhancement follows from the evidence reviewed here. The two study doses are described above; neither should be converted into a general supplementation recommendation.
Mushrooms provide dietary ergothioneine, with amounts that vary by species and preparation. There is no reason to treat a trial dose as a dietary target or calculate how much food is needed to reach it.
No optimal timing or combination regimen is established. Combining several antioxidant supplements does not demonstrate that their effects will add together.
Safety and Side Effects
The trial reported good short-term tolerability [1]. That does not establish long-term safety or a safe upper intake limit. Natural occurrence in food and authorization for a particular food use do not establish safety or effectiveness for every supplemental dose.
Drug-interaction information and evidence for pregnancy, breastfeeding, children, and people with significant medical conditions remain limited. A clinician or pharmacist can assess an individual's medications and circumstances before use.
How Ergothioneine Compares to Other Antioxidant Supplements
The antioxidant supplement market is crowded and often disappointing — large clinical trials of vitamin C, vitamin E, and beta-carotene have generally failed to show the benefits predicted by observational data and preclinical studies. Ergothioneine has several features that distinguish it from these predecessors:
1. Dedicated transporter. The body actively absorbs and retains ergothioneine, unlike most dietary antioxidants that are poorly absorbed or rapidly excreted.
2. Stability. Ergothioneine doesn't auto-oxidize or become pro-oxidant at high concentrations, a problem documented with vitamin C and vitamin E.
3. Tissue specificity. Accumulation in mitochondria, brain, and other high-stress tissues provides targeted rather than diffuse activity.
4. Clinical testing. Clinical evidence must be assessed by the prespecified outcome and comparison group, not by the presence of a trial alone.
These mechanistic features do not make ergothioneine a proven longevity intervention. Independent clinical replication and longer follow-up are needed.
Limitations of the Evidence
- Exploratory clinical evidence. The trial's primary result does not justify broad claims of improved memory.
- Population and formulation matter. Results from a defined study do not automatically apply to other populations or products.
- Long-term outcomes remain uncertain. A short study cannot establish effects on dementia incidence, lifespan, or long-term safety.
- Mechanisms are not outcomes. Laboratory effects and observational associations cannot establish that taking a supplement improves health.
The Verdict
Ergothioneine has biologically interesting properties, but those properties do not establish a favorable risk–benefit ratio for routine supplementation. Evidence for preventing dementia or extending life is insufficient.
The corrected trial interpretation supports continued research, not a universal 5–25 mg recommendation. Decisions about use should account for the uncertain benefit and the limits of available safety data.